Lifeboat Foundation

The future of microrobots!

Circa 2009

March 19, 2009 Researchers at the University of Miami and at the Universities of Tokyo and Tohoku, Japan, have been able to prove the existence of a “spin battery,” that could have significant applications including much faster, less expensive and use less energy consuming computer hard drives with no moving parts, and could even be developed to power cars.

A “spin battery” is “charged” by applying a large magnetic field to nano-magnets in a device called a magnetic tunnel junction (MTJ). Like a toy car, the spin battery is “wound up” by applying a large magnetic field — no chemistry involved.

Continue reading “Theoretical spin battery could see magnet powered cars” »

The strain is a part of the Group M version of HIV-1, the same family of virus subtypes to blame for the global HIV pandemic, according to Abbott Laboratories, which conducted the research along with the University of Missouri, Kansas City. The findings were published Wednesday in the Journal of Acquired Immune Deficiency Syndromes.

The Paul G. Allen Frontiers Group, a division of Seattle’s Allen Institute, is making a total of $7.5 million in awards to its latest class of five biomedical researchers.

The themes for this year’s Allen Distinguished Investigators focus on stem cell therapies and single-cell interactions in their native environments.

“The field of stem cell biology has the potential to change how we treat diseases by helping precision medicine, and there’s so much we still don’t understand about the interplay between cells in living tissues or organs,” Kathy Richmond, director of the Frontiers Group, said today in a news release.

A species of worm that can infect human eyes has done it again, and this time it chose a 68-year-old woman from Nebraska. The woman is thought to be only the second human victim of these worms ever documented. But the incident signals they could become an emerging parasitic disease in the U.S.

The disturbing details of the case were laid out in a paper published this October in the journal Clinical Infectious Diseases. The woman’s doctors, as well as researchers from the Centers for Disease Control and Prevention, contributed to the paper.

A lab-grown liver stand-in may better predict bad responses to drugs than animal testing does.

A human “liver chip” — liver cells grown on a membrane along with several types of supporting cells — formed structures reminiscent of bile ducts and reacted to drugs similarly to intact livers, researchers report November 6 in Science Translational Medicine. Similar rat and dog liver chips also processed drugs like normal livers in those species, allowing scientists to compare human liver cells’ reactions to drugs to those of the other species.

Rats, dogs and other animals are often used to test whether drugs are toxic to humans before the drugs are given to people. But a previous study found that the animal tests correctly identified only 71 percent of drug toxicities.

So far, a procedure that turbocharges the immune system to attack tumors seems safe, but it’s too soon to tell whether it helps patients.

Today we’re going to talk to the godfather of longevity, Aubrey de Grey, in the most ironic of settings – a pub in London. Over a beer, Aubrey explains why he believes that many of the typical health practices, such as drinking a lot of water, are myths and what he has discovered about slowing down the aging process. He reckons that in as little as 17 years, aging will no longer be a concern, and he supports this radical standpoint with some fascinating research. He talks about the idea that health is an integral part of longevity and that the seven pillars of aging need to be addressed simultaneously.

Human and animal longevity is directly bound to their health span. While previous studies have provided evidence supporting this connection, therapeutic implementation of this knowledge has been limited. Traditionally, diseases are researched and treated individually, which ignores the interconnectedness of age-related conditions, necessitates multiple treatments with unrelated substances, and increases the accumulative risk of side effects. In this study, we address and overcome this deadlock by creating adeno-associated virus (AAV)-based antiaging gene therapies for simultaneous treatment of several age-related diseases. We demonstrate the modular and extensible nature of combination gene therapy by testing therapeutic AAV cocktails that confront multiple diseases in a single treatment. We observed that 1 treatment comprising 2 AAV gene therapies was efficacious against all 4 diseases.

Comorbidity is common as age increases, and currently prescribed treatments often ignore the interconnectedness of the involved age-related diseases. The presence of any one such disease usually increases the risk of having others, and new approaches will be more effective at increasing an individual’s health span by taking this systems-level view into account. In this study, we developed gene therapies based on 3 longevity associated genes (fibroblast growth factor 21 [FGF21], αKlotho, soluble form of mouse transforming growth factor-β receptor 2 [sTGFβR2]) delivered using adeno-associated viruses and explored their ability to mitigate 4 age-related diseases: obesity, type II diabetes, heart failure, and renal failure.